Pharmacology
10 questionsWhich of the following is not an alpha-blocker?
Guanethidine is used in the treatment of which of the following conditions?
What is the primary therapeutic use of 5-HT1B/1D agonists?
Which enzyme is irreversibly inhibited by aspirin?
Side effects of thiazide diuretics include all of the following except?
Which of the following is an intermediate-acting insulin?
Long-term steroid ingestion leads to all of the following except:
Which antilipidemic drug reduces cholesterol levels by inhibiting cholesterol absorption?
Which sulphonamide has the longest acting duration?
All are true about ciprofloxacin except?
NEET-PG 2012 - Pharmacology NEET-PG Practice Questions and MCQs
Question 661: Which of the following is not an alpha-blocker?
- A. Atenolol (Correct Answer)
- B. Indoramine
- C. Idazoxan
- D. Prazosin
Explanation: ***Atenolol*** - Atenolol is a **selective beta-1 adrenergic receptor blocker**, primarily used to treat hypertension, angina, and certain arrhythmias. - Its mechanism of action involves **blocking the effects of adrenaline** on the heart, leading to decreased heart rate and blood pressure, rather than affecting alpha receptors. *Indoramine* - Indoramine is an **alpha-1 adrenergic receptor blocker** used historically for hypertension. - It specifically **antagonizes alpha-1 receptors** in vascular smooth muscle, causing vasodilation. *Idazoxan* - Idazoxan is an **alpha-2 adrenergic receptor antagonist**, primarily used in research contexts. - It **blocks presynaptic alpha-2 receptors**, which can lead to an increase in norepinephrine release. *Prazosin* - Prazosin is a well-known **alpha-1 adrenergic receptor blocker** used to treat hypertension and benign prostatic hyperplasia (BPH). - It causes **vasodilation** by relaxing vascular smooth muscle, thus lowering blood pressure.
Question 662: Guanethidine is used in the treatment of which of the following conditions?
- A. Ptosis
- B. Bell's palsy
- C. Thyrotoxic ophthalmopathy (Correct Answer)
- D. Horner's syndrome
Explanation: ***Thyrotoxic ophthalmopathy*** - Guanethidine is an **adrenergic neuron blocker** that can be used topically to reduce the sympathetic overactivity in the eye associated with thyrotoxicosis. - It helps alleviate symptoms like **retraction of the eyelids** and proptosis by blocking norepinephrine release from sympathetic nerve endings. *Ptosis* - **Ptosis** is primarily caused by weakness of the levator palpebrae superioris muscle or oculomotor nerve dysfunction, not sympathetic overactivity. - Guanethidine would not address the underlying muscular or neurologic deficit causing ptosis. *Bell's palsy* - **Bell's palsy** involves sudden, temporary weakness or paralysis of the muscles on one side of the face due to a dysfunction of the facial nerve. - Treatment typically involves corticosteroids and antivirals; guanethidine has no role in its management. *Horner's syndrome* - **Horner's syndrome** is characterized by miosis, ptosis, and anhidrosis, resulting from damage to the sympathetic nerve supply to the eye and face. - Guanethidine's mechanism of action would exacerbate, rather than treat, the existing sympathetic deficit in Horner's syndrome.
Question 663: What is the primary therapeutic use of 5-HT1B/1D agonists?
- A. Anti-anxiety medications
- B. Acute migraine treatment (Correct Answer)
- C. Anti-nausea medications for chemotherapy
- D. Drugs for gastroesophageal reflux disease (GERD)
Explanation: ***Acute migraine treatment*** - 5-HT1B/1D agonists, such as **triptans**, primarily work by causing **vasoconstriction of intracranial blood vessels** and inhibiting the release of pro-inflammatory neuropeptides. - This action directly alleviates the pain and associated symptoms of **acute migraine attacks**. *Anti-anxiety medications* - Anti-anxiety medications typically target neurotransmitter systems like **GABA** (e.g., benzodiazepines) or **serotonin reuptake** (e.g., SSRIs), not the 5-HT1B/1D receptors in this context. - While serotonin plays a role in anxiety, specific 5-HT1B/1D agonism does not lead to anxiolytic effects. *Anti-nausea medications for chemotherapy* - Anti-nausea medications used for chemotherapy-induced nausea and vomiting often target **5-HT3 receptors** (e.g., ondansetron) to block their pro-emetic effects. - 5-HT1B/1D agonists do not have primary anti-emetic properties useful in this setting. *Drugs for gastroesophageal reflux disease (GERD)* - GERD medications primarily focus on reducing stomach acid production (e.g., **proton pump inhibitors**, H2 blockers) or neutralizing it (antacids). - 5-HT1B/1D agonists do not directly influence gastric acid secretion or esophageal motility in a way beneficial for GERD.
Question 664: Which enzyme is irreversibly inhibited by aspirin?
- A. Lipooxygenase
- B. Cyclooxygenase (Correct Answer)
- C. Thromboxane synthase
- D. Phospholipase
Explanation: ***Cyclooxygenase*** - **Aspirin** irreversibly inhibits **cyclooxygenase (COX-1 and COX-2)** by acetylating a serine residue in the enzyme's active site. - This irreversible inhibition prevents the production of **prostaglandins, thromboxane**, and **prostacyclin**, thereby reducing inflammation, pain, fever, and platelet aggregation. *Lipooxygenase* - **Lipooxygenase** is involved in the synthesis of **leukotrienes**, which are mediators of inflammation and allergic responses. - Aspirin does not directly inhibit lipooxygenase; rather, it primarily targets the COX pathway. *Thromboxane synthase* - **Thromboxane synthase** is an enzyme downstream of COX, responsible for converting prostaglandin H2 into **thromboxane A2**. - While aspirin's effect on platelet aggregation is due to reduced thromboxane A2 synthesis via COX inhibition, it does not directly inhibit thromboxane synthase itself. *Phospholipase* - **Phospholipase A2** is responsible for releasing **arachidonic acid** from cell membrane phospholipids, which is the initial step in both the cyclooxygenase and lipooxygenase pathways. - Aspirin does not directly inhibit phospholipase A2; its action occurs later in the cascade.
Question 665: Side effects of thiazide diuretics include all of the following except?
- A. Hypokalemia
- B. Erectile dysfunction
- C. Hyponatremia
- D. Hypocalcemia (Correct Answer)
Explanation: ***Hypocalcemia*** - Thiazide diuretics are known to cause **hypercalcemia** (increased calcium reabsorption), NOT hypocalcemia, due to their action on the distal convoluted tubule. - This property makes them useful in treating conditions like **idiopathic hypercalciuria** and **calcium-containing kidney stones**. - The mechanism involves enhanced passive calcium reabsorption in the proximal tubule and active reabsorption in the distal tubule. *Hyponatremia* - Thiazide diuretics impair the kidney's ability to dilute urine and reabsorb sodium in the distal tubule, leading to **increased sodium excretion** and potential hyponatremia. - This effect is more pronounced in **elderly patients** and those with increased free water intake. - Hyponatremia is one of the most common electrolyte disturbances with thiazides. *Hypokalemia* - Thiazides increase the delivery of sodium and water to the collecting duct, leading to increased activity of the **renin-angiotensin-aldosterone system** and enhanced potassium secretion. - This results in **potassium wasting** and hypokalemia, which may require potassium supplementation or combination with potassium-sparing diuretics. *Erectile dysfunction* - Thiazide diuretics can cause **erectile dysfunction** through mechanisms including effects on vascular smooth muscle, reduced blood flow, and possible hormonal effects. - This is a common side effect reported in male patients using these medications for hypertension and may affect compliance.
Question 666: Which of the following is an intermediate-acting insulin?
- A. Insulin lispro
- B. NPH insulin (Correct Answer)
- C. Insulin glargine
- D. Regular insulin
Explanation: ***NPH insulin*** - **NPH (Neutral Protamine Hagedorn) insulin** is characterized by its intermediate duration of action, typically peaking in 4-12 hours and lasting up to 24 hours [1]. - This intermediate profile is achieved by combining insulin with **protamine**, which slows its absorption from the subcutaneous injection site [1]. *Insulin lispro* - **Insulin lispro** is a **rapid-acting insulin** analog, designed to act very quickly after injection, typically within 15-30 minutes [1, 2]. - Its quick onset and short duration make it suitable for dosing **immediately before meals** to control post-prandial glucose levels [1]. *Regular insulin* - **Regular insulin** is a **short-acting insulin**, with an onset of action around 30-60 minutes and a peak effect typically within 2-4 hours. - It is often administered **30 minutes before meals** and can also be used intravenously in acute situations like diabetic ketoacidosis. *Insulin glargine* - **Insulin glargine** is a **long-acting insulin** analog, providing a prolonged and relatively peakless effect over 24 hours [1, 2]. - Its primary role is to provide **basal insulin coverage**, mimicking the body's continuous background insulin production [1, 2].
Question 667: Long-term steroid ingestion leads to all of the following except:
- A. Avascular necrosis of head of femur
- B. Growth retardation
- C. Hypoglycemia (Correct Answer)
- D. Cataract
Explanation: ***Hypoglycemia*** - Chronic steroid use primarily leads to **hyperglycemia** due to increased **gluconeogenesis** and **insulin resistance**, not hypoglycemia. - Steroids raise blood glucose levels, potentially inducing or worsening **diabetes mellitus**. *Avascular necrosis of head of femur* - Long-term steroid use is a well-established risk factor for **avascular necrosis**, particularly affecting the **femoral head**. - This occurs due to impaired blood supply to the bone, leading to its death. *Cataract* - **Posterior subcapsular cataracts** are a known ocular complication of prolonged systemic corticosteroid therapy. - The mechanism involves direct effects of steroids on lens metabolism and protein aggregation. *Growth retardation* - In children, chronic corticosteroid therapy can suppress growth, leading to **growth retardation**. - This is due to interference with **growth hormone secretion** and direct effects on bone formation.
Question 668: Which antilipidemic drug reduces cholesterol levels by inhibiting cholesterol absorption?
- A. Ezetimibe (Correct Answer)
- B. Orlistat
- C. Cholestyramine
- D. Statins
Explanation: ***Ezetimibe*** - **Ezetimibe** selectively inhibits the **Niemann-Pick C1-Like 1 (NPC1L1) protein**, which is responsible for plant sterol and cholesterol absorption in the small intestine. - This action leads to a reduction in **LDL-C** levels by decreasing the amount of cholesterol available to the liver. *Orlistat* - **Orlistat** is a **lipase inhibitor** that prevents the absorption of dietary fats by inhibiting gastric and pancreatic lipases. - While it aids in weight loss and can indirectly improve lipid profiles, its primary mechanism is *not* direct inhibition of cholesterol absorption. *Cholestyramine* - **Cholestyramine** is a **bile acid sequestrant** that binds to bile acids in the intestine, preventing their reabsorption. - This increases the excretion of bile acids, prompting the liver to synthesize more bile acids from cholesterol, thereby lowering cholesterol levels, but it does *not* directly inhibit cholesterol absorption. *Statins* - **Statins** (HMG-CoA reductase inhibitors) are considered first-line agents for lowering cholesterol by inhibiting the **rate-limiting step in cholesterol synthesis** in the liver. - Their primary action is to reduce endogenous cholesterol production, not to block cholesterol absorption from the gut.
Question 669: Which sulphonamide has the longest acting duration?
- A. Sulfadiazine
- B. Sulphadoxine (Correct Answer)
- C. Sulfamethoxazole
- D. Sulfamethiazole
Explanation: ***Sulphadoxine*** - **Sulphadoxine** is known for its **exceptionally long elimination half-life**, which is due to its high plasma protein binding and slow renal excretion. - This property allows for **once-weekly dosing**, making it one of the longest-acting sulfonamides, often used in combinations for malaria prophylaxis or treatment. *Sulfadiazine* - **Sulfadiazine** has an intermediate half-life, typically requiring **multiple daily doses**. - It is commonly used for infections like **toxoplasmosis** and **nocardiosis**. *Sulfamethoxazole* - **Sulfamethoxazole** has an intermediate half-life, usually requiring **twice-daily administration**. - It is most famously co-formulated with **trimethoprim** (as co-trimoxazole) for a broad range of bacterial infections. *Sulfamethiazole* - **Sulfamethiazole** is a **short-acting sulfanilamide derivative** with a rapid elimination, meaning it would require frequent dosing. - It is not commonly used systemically due to its short duration of action.
Question 670: All are true about ciprofloxacin except?
- A. More active at acidic pH (Correct Answer)
- B. DNA gyrase inhibition
- C. Contraindicated in pregnancy
- D. Second generation fluoroquinolone
Explanation: ***More active at acidic pH*** - Fluoroquinolones, including ciprofloxacin, exhibit **reduced antibacterial activity in acidic environments**. Their efficacy is generally better at **neutral or alkaline pH**. - This is clinically relevant as fluoroquinolones may have **reduced effectiveness in acidic sites** like the stomach or acidic urine. - The optimal antibacterial activity occurs at physiological or slightly alkaline pH. *DNA gyrase inhibition* - Ciprofloxacin, like other fluoroquinolones, exerts its antibacterial effect by inhibiting **bacterial DNA gyrase (topoisomerase II)** and **topoisomerase IV**. - This inhibition prevents DNA replication and repair, leading to bacterial cell death. *Contraindicated in pregnancy* - Ciprofloxacin is generally **contraindicated in pregnancy** due to concerns about potential harm to the developing fetus, particularly effects on **cartilage development**. - However, it may be used in specific, life-threatening situations if the benefit outweighs the potential risk. *Second generation fluoroquinolone* - Ciprofloxacin is classified as a **second-generation fluoroquinolone**. - This class includes agents with improved activity against Gram-negative bacteria and some atypical organisms.